oral reversible ERK1/2 kinase inhibitor combo eff. w/ MEKi in mKRAS model; in Ph. I from historical kinase sel. data, SBDD + opt. Mol. Cancer Ther. Dec. 3, 2020 AstraZeneca, Cambridge, UK